The current market price of Nippon India NIFTY Pharma ETF Growth Plan is ₹22.47. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.

Nippon India NIFTY Pharma ETF Growth Plan, managed by Nippon Life India Asset Management, is an Equity - ETF employing a passive approach to directly replicate Nifty Pharma TRI constituents. The fund passively tracks Nifty Pharma TRI through full-index proportionate exposure, displaying tight tracking efficiency with a tracking error of 0.0% and expense ratio of 0.2% supporting index replication efforts. Portfolio concentration is pronounced in Pharmaceuticals & Biotechnology at 99.9%, led by Sun Pharmaceutical 21.3%, Divi's 9.7%, Cipla 9.4% and Dr. Reddy's 9.4%, cash 0.1% and notable midcap allocations remain. Performance over available period shows 1Y: +1.7% with tracking error of 0.0% underscoring tight index alignment, while limited additional period data precludes longer term compound return commentary in this dataset. The ETF reported AUM ₹1007.5 Cr as on Jan 2026 (monthly average ₹1007.0 Cr), managed by Jitendra Tolani since Feb 2025 with 19 years' experience and expense ratio 0.2% overall.

Nippon India NIFTY Pharma ETF Growth Plan is designed to track Nifty Pharma TRI, allowing investors to gain exposure to its underlying securities through a single investment.

The expense ratio of Nippon India NIFTY Pharma ETF Growth Plan is 0.21%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.

The Assets Under Management (AUM) of Nippon India NIFTY Pharma ETF Growth Plan is approximately ₹1,007.47. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.

Nippon India NIFTY Pharma ETF Growth Plan is classified under the Very High risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.

The tracking error of Nippon India NIFTY Pharma ETF Growth Plan is 0.02%. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.

Nippon India NIFTY Pharma ETF Growth Plan has a dividend yield of 0.70%. Dividend treatment depends on the ETF structure and fund house policy.

Based on available data, Nippon India NIFTY Pharma ETF Growth Plan has delivered the following returns: 1-year return: 0.58%. 3-year return: 0.58%. 5-year return: 0.58%. Past performance does not guarantee future results.

Before investing in Nippon India NIFTY Pharma ETF Growth Plan, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.